# SG301-SC Injection Safety Study in Subjects With Primary ITP Patients

> clinical trial · VERIFIED · 2026-07-17

Status: RECRUITING · Sponsor: Hangzhou Sumgen Biotech Co., Ltd. · Condition: Primary Immune Thrombocytopenia

- Company: Hangzhou Sumgen Biotech Co., Ltd.
- Sector: Primary Immune Thrombocytopenia
- Primary source: https://clinicaltrials.gov/study/NCT07710248

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.